MX2017013885A - Compuestos de indolona y su uso como moduladores del receptor ampa. - Google Patents
Compuestos de indolona y su uso como moduladores del receptor ampa.Info
- Publication number
- MX2017013885A MX2017013885A MX2017013885A MX2017013885A MX2017013885A MX 2017013885 A MX2017013885 A MX 2017013885A MX 2017013885 A MX2017013885 A MX 2017013885A MX 2017013885 A MX2017013885 A MX 2017013885A MX 2017013885 A MX2017013885 A MX 2017013885A
- Authority
- MX
- Mexico
- Prior art keywords
- receptor modulators
- ampa receptor
- compounds
- indolone compounds
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Traffic Control Systems (AREA)
- Medicinal Preparation (AREA)
Abstract
Se proporcionan en la presente descripción compuestos de la Fórmula (I), y sales farmacéuticamente aceptables, N-óxidos o solvatos de éstos; (ver Fórmula) la presente descripción proporciona, además, composiciones farmacéuticas, que comprenden compuestos de la Fórmula (I), y métodos para usar los compuestos de la Fórmula (I).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562154315P | 2015-04-29 | 2015-04-29 | |
PCT/US2016/029805 WO2016176463A1 (en) | 2015-04-29 | 2016-04-28 | Indolone compounds and their use as ampa receptor modulators |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2017013885A true MX2017013885A (es) | 2018-06-13 |
MX369806B MX369806B (es) | 2019-11-21 |
Family
ID=55919909
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017013885A MX369806B (es) | 2015-04-29 | 2016-04-28 | Compuestos de indolona y su uso como moduladores del receptor ampa. |
Country Status (11)
Country | Link |
---|---|
US (1) | US10604484B2 (es) |
EP (1) | EP3288935B1 (es) |
JP (1) | JP6811187B2 (es) |
KR (1) | KR20170141769A (es) |
CN (1) | CN107750250B (es) |
AU (1) | AU2016256413B2 (es) |
BR (1) | BR112017023200A2 (es) |
CA (1) | CA2984305C (es) |
ES (1) | ES2767707T3 (es) |
MX (1) | MX369806B (es) |
WO (1) | WO2016176463A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019070043A1 (ja) * | 2017-10-06 | 2019-04-11 | 武田薬品工業株式会社 | 複素環化合物 |
EP3693360B1 (en) | 2017-10-06 | 2023-12-13 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS55167282A (en) | 1979-06-12 | 1980-12-26 | Fujisawa Pharmaceut Co Ltd | Piperazine derivative or its salt and its preparation |
TW251284B (es) | 1992-11-02 | 1995-07-11 | Pfizer | |
US5688809A (en) | 1994-02-10 | 1997-11-18 | Pfizer Inc. | 5-heteroarylindole derivatives |
US5565483A (en) * | 1995-06-07 | 1996-10-15 | Bristol-Myers Squibb Company | 3-substituted oxindole derivatives as potassium channel modulators |
UA54403C2 (uk) * | 1996-10-01 | 2003-03-17 | Н'Юросерч А/С | Похідні індол-2,3-діон-3-оксиму, фармацевтична композиція, спосіб лікування розладу чи захворювання ссавців, у тому числі людини та спосіб одержання похідних індол-2,3-діон-3-оксиму |
DE19812331A1 (de) * | 1998-03-20 | 1999-09-23 | Merck Patent Gmbh | Piperidinderivate |
JP2002519373A (ja) | 1998-07-02 | 2002-07-02 | エーザイ株式会社 | 製薬組成物及びそれらの使用 |
GB0018473D0 (en) | 2000-07-27 | 2000-09-13 | Merck Sharp & Dohme | Therapeutic agents |
AU2001282865A1 (en) | 2000-08-11 | 2002-02-25 | Eli Lilly And Company | Heterocyclic sulfonamide derivatives |
CN101052640B (zh) | 2004-09-03 | 2011-05-11 | 默克雪兰诺有限公司 | 吡啶亚甲基唑烷酮类及其作为磷酸肌醇抑制剂的用途 |
DE602006019119D1 (de) * | 2005-09-30 | 2011-02-03 | Glaxo Group Ltd | Verbindungen mit aktivität am m1-rezeptor und ihre verwendung in der medizin |
WO2007135529A2 (en) | 2006-05-23 | 2007-11-29 | Pfizer Products Inc. | Azabenzimidazolyl compounds as mglur2 potentiators |
DE602007013450D1 (de) | 2006-11-03 | 2011-05-05 | Glaxo Group Ltd | Verbindungen, die den ampa-rezeptor verstärken, und deren anwendung in der medizin |
WO2008113795A1 (en) | 2007-03-20 | 2008-09-25 | Glaxo Group Limited | Compounds which potentiate ampa receptor and uses thereof in medicine |
GB0711089D0 (en) | 2007-06-08 | 2007-07-18 | Glaxo Group Ltd | Compounds |
WO2010005528A2 (en) | 2008-06-30 | 2010-01-14 | Ironwood Pharmaceuticals Incorporated | Pyrrolopyridine carboxylic acid derivatives |
GB0822425D0 (en) | 2008-12-09 | 2009-01-14 | Glaxo Group Ltd | Compounds |
WO2011056985A2 (en) * | 2009-11-04 | 2011-05-12 | Gilead Sciences, Inc. | Substituted heterocyclic compounds |
WO2011156245A2 (en) | 2010-06-09 | 2011-12-15 | Merck Sharp & Dohme Corp. | Positive allosteric modulators of mglur2 |
US8993779B2 (en) * | 2010-08-12 | 2015-03-31 | Merck Sharp & Dohme Corp. | Positive allosteric modulators of MGLUR2 |
BR112014010368A2 (pt) | 2011-10-31 | 2017-04-25 | Xenon Pharmaceuticals Inc | biaril éter sulfonamidas e seu uso como agentes terapêuticos |
JO3225B1 (ar) | 2012-11-27 | 2018-03-08 | Lilly Co Eli | 6-((s)-1-{1-[5-(2-هيدروكسي-إيثوكسي)-بيريدين-2-يل]-1h-بيرازول-3-يل}إيثيل)-3h-1 ، 3-بنزو ثيازول-2- أون باعتباره مضاد مستقبل ampa يعتمد على tarp- جاما 8 |
MX2015010714A (es) | 2013-02-19 | 2016-06-14 | Pfizer | Compuestos de azabencimidazol. |
-
2016
- 2016-04-28 EP EP16721040.0A patent/EP3288935B1/en active Active
- 2016-04-28 JP JP2017556532A patent/JP6811187B2/ja active Active
- 2016-04-28 US US15/569,313 patent/US10604484B2/en not_active Expired - Fee Related
- 2016-04-28 CA CA2984305A patent/CA2984305C/en active Active
- 2016-04-28 BR BR112017023200-6A patent/BR112017023200A2/pt not_active Application Discontinuation
- 2016-04-28 CN CN201680024581.XA patent/CN107750250B/zh not_active Expired - Fee Related
- 2016-04-28 MX MX2017013885A patent/MX369806B/es active IP Right Grant
- 2016-04-28 ES ES16721040T patent/ES2767707T3/es active Active
- 2016-04-28 AU AU2016256413A patent/AU2016256413B2/en not_active Ceased
- 2016-04-28 KR KR1020177034370A patent/KR20170141769A/ko not_active Application Discontinuation
- 2016-04-28 WO PCT/US2016/029805 patent/WO2016176463A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
AU2016256413A1 (en) | 2017-10-19 |
US20180118683A1 (en) | 2018-05-03 |
JP6811187B2 (ja) | 2021-01-13 |
JP2018514543A (ja) | 2018-06-07 |
MX369806B (es) | 2019-11-21 |
KR20170141769A (ko) | 2017-12-26 |
NZ736056A (en) | 2021-07-30 |
CN107750250A (zh) | 2018-03-02 |
BR112017023200A2 (pt) | 2018-08-07 |
CA2984305A1 (en) | 2016-11-03 |
ES2767707T3 (es) | 2020-06-18 |
US10604484B2 (en) | 2020-03-31 |
WO2016176463A1 (en) | 2016-11-03 |
EP3288935A1 (en) | 2018-03-07 |
EP3288935B1 (en) | 2019-10-30 |
CA2984305C (en) | 2021-12-28 |
CN107750250B (zh) | 2021-09-07 |
AU2016256413B2 (en) | 2020-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JO3654B1 (ar) | مركبات ازا بنزيميدازول واستخدامها كمعدلات للمستقبلات ذات النمط الإمبائي (ampa) | |
PH12018500591A1 (en) | Heterocyclic compounds and uses thereof | |
PH12017501191B1 (en) | Quinazoline derivatives used to treat hiv | |
MX2017008520A (es) | Compuestos de pirimidina fusionada para el tratamiento del virus de inmunodeficiencia humana (vih). | |
PH12016501440A1 (en) | Novel heterocyclic compounds | |
MX2017013877A (es) | Compuestos de benzimidazolona y benzotiazolona y su uso como moduladores del receptor ampa. | |
NZ737399A (en) | Ccr2 modulators | |
MX2016011632A (es) | Derivados de azaspiro como antagonistas de trpm8. | |
MX2017008518A (es) | Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih). | |
MX2016011992A (es) | Derivados de piperidina-diona. | |
MX2017013874A (es) | Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa. | |
PH12019501639A1 (en) | Jaki selective inhibitors | |
TW201613864A (en) | Novel compounds | |
ZA201903291B (en) | Fused bicylic pyridine compounds and their use as ampa receptor modulators | |
MX2017009292A (es) | Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3. | |
MD20160100A2 (ro) | Urei asimetrice p-substituite şi utilizările medicale ale acestora | |
MX369806B (es) | Compuestos de indolona y su uso como moduladores del receptor ampa. | |
EA201991045A1 (ru) | Конденсированные азагетероциклические соединения и их применение в качестве модуляторов ampa-рецептора | |
MX2016015959A (es) | Derivados de carbamato los cuales son tanto inhibidores de la enzima fosfodiesterasa 4 (pde4) como antagonistas del receptor muscarinico m3. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |